Avastin wins new regulatory approval

Watch a blockbuster cancer drug become a behemoth: Roche has won European regulatory approval for treatment of advanced non-small cell lung cancer with Avastin. The approval came on the strength of trials that showed "improved survival benefits beyond one year in NSCLC patients," the company said. It's the first new treatment for NSCLC in more than 10 years that's demonstrated an ability to extend patients' lives.

This is Avastin's third indication for cancer treatment in Europe. Previously the drug has been used to treat metastatic colorectal cancer and breast cancer there; in the U.S. it's also approved for NSCLC. Roche is exploring its use in pancreatic and ovarian cancers, among others. Already this year, Avastin sales have topped $1.5 billion, 40 percent higher than last year's first-half figures.

- see this announcement on the approval
- check out the AP report

Related Articles:
Patients balk at Avastin's $100,000 price tag. Report
Avastin encounters rare failure for pancreatic cancer. Report
FDA approves Avastin for lung cancer. Report

Suggested Articles

Pfizer isn't giving up in biosims. This week, it unveiled launches to three Roche blockbusters, with two already on the market.

Novo Nordisk is betting big on GLP-1 Saxenda in its global obesity push, but England's cost watchdog is unimpressed with the drug's long-term outlook.

Tecentriq didn’t show benefit against simple observation at delaying cancer recurrence or death in patients with muscle-invasive urothelial cancer.